Bayer to Buy Perfuse Therapeutics in 2.45 Billion Deal
Bayer will buy Perfuse Therapeutics for up to $2.45 billion to expand its eye care pipeline. The deal includes $300 million upfront for a phase II glaucoma drug.
Xurve View
Insights:
Xurve View
BAYER AG-REG will acquire biopharmaceutical firm Perfuse Therapeutics in a deal valued at up to $2.45 billion. The agreement includes a $300 million upfront payment alongside milestone-based incentives for development and commercial success. This acquisition secures full rights to a Phase II asset, strengthening Bayer's ophthalmology pipeline as it seeks new growth drivers.
